manchestereveningnews.co.uk
45%
708
Novavax coronavirus vaccine has 89% efficacy and strong protection against variant, trials show
direct to your inboxA new vaccine against Covid-19 has over 89% efficacy, trial results have shown.UK phase three trials of the Novavax Covid-19 vaccine have found it demonstrated 89.3% efficacy against the virus.Preliminary analysis has also showed the new UK variant was detected in more than half of the Covid-19 cases recorded in the trials, with the vaccine candidate shown to be 95.6% effective against the original strain and 85.6% effective against the variant.The study involved more than 15,000 participants aged 18 to 84, with 27% aged over 65.Clive Dix, chairman of the UK Vaccine Taskforce, said: “These are spectacular results, and we are very pleased to have helped Novavax with the development of this vaccine.